Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Turn Therapeutics direct listing
We advised Turn Therapeutics on its Nasdaq listing
Oruka Therapeutics $200 million at-the-market offering
We advised Oruka on the offering
Mirion Technologies concurrent stock and convertible notes offerings
We advised Mirion Technologies on its $425 million stock offering and concurrent $375 million convertible notes offering
Amulet Capital Partners sale of SSI Strategy to Clinigen
We are advising Amulet Capital Partners and SSI Strategy on the sale
Medtronic €1.5 billion notes offering
The investment-grade notes are due 2030 and 2045
MBX Biosciences $200 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Laekna HK$587 million placement of shares
We advised Laekna on the placement of new shares
Strive acquisition of Semler Scientific
We are advising Strive on the acquisition
Oruka Therapeutics $180 million private placement
The PIPE included common stock and pre-funded warrants
GenFleet Therapeutics HK$1.82 billion IPO
We advised GenFleet on its IPO and HKEX listing